Lewy

Amprion Announces Presentation of Findings Related to Usage of the αSynuclein Seed Amplification Assay in Recent Parkinson's Study at 2023 AAN Annual Meeting

Retrieved on: 
Friday, April 21, 2023

SAN DIEGO, April 21, 2023 /PRNewswire/ -- Amprion is pleased to announce that it will attend the American Academy of Neurology (AAN) Annual Meeting in Boston April 22-27 to share insights about its SYNTap Biomarker Test, a first-in-class qualitative Laboratory Developed Test (LDT) and the only seed amplification assay available to aid physicians in diagnosing synucleinopathies.

Key Points: 
  • To learn more about SYNTap during the meeting, attendees can visit the Exhibit Hall to:
    Meet with the Amprion team in Booth 668.
  • Attend Dr. Andrew Siderowf's presentation at 2 p.m. EST on Monday, April 24 on the Emerging Neurologic Care Presentation Stage.
  • The talk is titled "High Diagnostic Accuracy of Amprion's SAA Assay Informs PD Heterogeneity and Disease Onset in Analysis of the PPMI Cohort."
  • In his presentation, Dr. Siderowf will discuss how Amprion's αSyn Seed Amplification Assay was utilized in the landmark PPMI paper, which was published in The Lancet Neurology journal on April 12, 2023.

Cognition Therapeutics Announces New Episode of “Conversations” Podcast: Insights for the Primary Care Physician: Recognizing Dementia with Lewy Bodies

Retrieved on: 
Monday, March 27, 2023

PURCHASE, N.Y., March 27, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX) (the “Company” or “Cognition”) has released its fourth “Conversations” video podcast, a two-part conversation about dementia with Lewy bodies (DLB) focusing on the overlapping symptoms and pathology of DLB, Alzheimer's and Parkinson's diseases.

Key Points: 
  • PURCHASE, N.Y., March 27, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX) (the “Company” or “Cognition”) has released its fourth “Conversations” video podcast, a two-part conversation about dementia with Lewy bodies (DLB) focusing on the overlapping symptoms and pathology of DLB, Alzheimer's and Parkinson's diseases.
  • Four neuroscience thought leaders with a wealth of experience in diagnosing and managing dementia share their insights into the nuanced symptoms and signs that help them differentiate DLB from other dementias such as Alzheimer’s disease.
  • Episode 4: “Insights for the Primary Care Physician: Recognizing Dementia with Lewy Bodies” features a conversation between:
    Brendan Kelley, M.D., (moderator) vice chair for clinical operations at the Peter O’Donnell Jr.
  • We’d love to hear your thoughts!

Amprion showcases SYNTap® Biomarker Test at AD/PD™ 2023 International Conference

Retrieved on: 
Monday, March 27, 2023

SAN DIEGO, March 27, 2023 /PRNewswire/ -- Amprion is pleased to announce its attendance at the AD/PD™ 2023 International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders in Gothenburg, Sweden on March 28-April 1. Amprion's findings will be highlighted in one oral presentation on Friday, March 31st 16:50 CET in hall G4 during the Alpha-Synuclein, PD Mechanistic Aspects Symposium, and in three posters located within the exhibition hall. Please see below for more information. Amprion's SYNTap Biomarker Test is a first-in-class-qualitative Laboratory Developed Test (LDT) and the only seed amplification assay available to aid the diagnosis of synucleinopathies.

Key Points: 
  • Amprion's SYNTap Biomarker Test is a first-in-class-qualitative Laboratory Developed Test (LDT) and the only seed amplification assay available to aid the diagnosis of synucleinopathies.
  • "It is estimated that around 44 million people worldwide are living with Alzheimer's disease or a related form of dementia.
  • "Amprion is committed to positively impacting brain disease diagnosis, which will help accelerate life-saving drug development for patients suffering from these diseases.
  • SYNTap will also be presented in the context of three posters, located in the Exhibition Area for all conference days that the Exhibition is open:

Olatec Therapeutics Awarded a Grant from The Michael J. Fox Foundation in Collaboration With Medical University of Innsbruck to Evaluate Dapansutrile in Animal Models of Parkinson’s Disease Progression

Retrieved on: 
Friday, March 10, 2023

Olatec Therapeutics LLC (Olatec), a leader in the developing class of selective NLRP3 inhibitors, today announced that The Michael J.

Key Points: 
  • Olatec Therapeutics LLC (Olatec), a leader in the developing class of selective NLRP3 inhibitors, today announced that The Michael J.
  • Fox Foundation for Parkinson’s Research (MJFF) awarded a research grant to evaluate Olatec’s lead molecule, dapansutrile, in preclinical Parkinson’s disease (PD) progression models.
  • These studies are being initiated in collaboration with researchers at the Medical University of Innsbruck in Austria.
  • Nadia Stefanova MD PhD, the lead investigator on this study, is a professor in the Department of Neurology, Medical University of Innsbruck.

Cognition Therapeutics Highlights Phase 2 SHIMMER Study of CT1812 in Dementia with Lewy Bodies in Presentation at CTAD

Retrieved on: 
Monday, November 28, 2022

The Phase 2 SHIMMER (COG1201) study is intended to assess the safety, tolerability, and efficacy of CT1812 in individuals with dementia with Lewy bodies (DLB).

Key Points: 
  • The Phase 2 SHIMMER (COG1201) study is intended to assess the safety, tolerability, and efficacy of CT1812 in individuals with dementia with Lewy bodies (DLB).
  • The SHIMMER study is being conducted at over 30 sites in the United States, many of which are LBDA centers of excellence.
  • DLB is caused by a build-up of a protein, -synuclein, which forms deposits, called Lewy bodies, in the brain.
  • We are currently investigating our lead candidate CT1812 in clinical programs in Alzheimers disease, dementia with Lewy bodies (DLB) and dry age-related macular degeneration (dry AMD).

Lucy Therapeutics Debuts Novel Therapeutic Agents for Parkinson’s Disease at Michael J. Fox Foundation Annual Conference

Retrieved on: 
Thursday, October 13, 2022

Fox Foundation's 14th annual Parkinson's Disease Therapeutics Conference on October 13, 2022, in New York City.

Key Points: 
  • Fox Foundation's 14th annual Parkinson's Disease Therapeutics Conference on October 13, 2022, in New York City.
  • We have demonstrated that our compounds can rescue neurons in cellular models of Parkinsons disease, validating our therapeutic approach.
  • "Lucy Therapeutics wants to create a world in which mitochondrial-involved neurological diseases like Parkinsons or Rett syndrome can be halted when diagnosed, said Amy Ripka, Ph.D., founder and CEO of Lucy Therapeutics.
  • Fox Foundation for Parkinsons Research , Lucy Therapeutics has received support tallying $24 million as of October 2022, from Pivotal bioVenture Partners, Safar Partners, The Engine and the Massachusetts Life Science Center.

Cognition Therapeutics is Recruiting for Lewy Body Dementia Phase 2 SHIMMER Trial in Seventeen Research Sites Across the U.S.

Retrieved on: 
Wednesday, October 12, 2022

The Phase 2 SHIMMER study ( NCT05225415 ) is actively recruiting participants for these sites across the United States, including those that are Lewy Body Dementia Association centers of excellence added Anthony O. Caggiano, M.D., Ph.D., Cognitions chief medical officer and head of R&D.

Key Points: 
  • The Phase 2 SHIMMER study ( NCT05225415 ) is actively recruiting participants for these sites across the United States, including those that are Lewy Body Dementia Association centers of excellence added Anthony O. Caggiano, M.D., Ph.D., Cognitions chief medical officer and head of R&D.
  • This month is Lewy Body Dementia Awareness month with approximately over 1.4 million people in the United States suffering from the neurodegenerative disease, making it the second most common form of dementia.
  • Often misdiagnosed it also masks itself as Parkinsons disease and is the largest dementia most have never heard of.
  • This October, during Lewy Body Dementia Awareness Month, lets recommit to educating ourselves about LBD.

EIP Pharma Publishes Translational Data of Preclinical and Phase 2a Results for Neflamapimod in Dementia with Lewy Bodies: Nature Communications

Retrieved on: 
Wednesday, September 21, 2022

The animal studies in the publication show that neflamapimod reduces Rab5 activity and reverses the neurodegenerative process in the basal forebrain.

Key Points: 
  • The animal studies in the publication show that neflamapimod reduces Rab5 activity and reverses the neurodegenerative process in the basal forebrain.
  • These combined pre-clinical and clinical results provide a foundation for a confirmatory, hypothesis-testing Phase 2b clinical study evaluating neflamapimod for DLB.
  • The data published today provide us confidence to progress neflamapimod into a confirmatory Phase 2b clinical trial in Dementia with Lewy Bodies.
  • et al., Preclinical and Randomized Clinical Evaluation of the p38 Kinase Inhibitor Neflamapimod for Basal Forebrain Cholinergic Degeneration, Nature Communications, 13, Article number: 5308 (2022).

Cognition Therapeutics Doses First Patient with Dementia with Lewy Bodies in Phase 2 Clinical Study of CT1812

Retrieved on: 
Thursday, June 23, 2022

NEW YORK, June 23, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX) today announced that the first patient has been dosed in its double-blind, placebo-controlled, randomized Phase 2 SHIMMER clinical trial of CT1812 in patients with dementia with Lewy bodies (DLB). CT1812 is an experimental, orally delivered small molecule therapeutic intended to address the underlying biology of DLB.

Key Points: 
  • NEW YORK, June 23, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics , Inc. (Nasdaq: CGTX) today announced that the first patient has been dosed in its double-blind, placebo-controlled, randomized Phase 2 SHIMMER clinical trial of CT1812 in patients with dementia with Lewy bodies (DLB) .
  • Further evidence suggests that these processes are regulated by the sigma-2 (-2) receptor, which is the biological target of CT1812.
  • Initiation of patient treatment in this interventional study is an important milestone for Cognition Therapeutics and for the DLB community.
  • We are currently investigating our lead candidate CT1812 in clinical programs in Alzheimers disease, dementia with Lewy bodies (DLB) and dry age-related macular degeneration (dry AMD).

Seelos Therapeutics Receives a Notice of Allowance in the U.S. for an Additional Patent for SLS-007

Retrieved on: 
Wednesday, May 18, 2022

Seelos is currently delivering SLS-007 via an adeno-associated virus (AAV) in a preclinical study designed to establish the in vivo pharmacokinetic and pharmacodynamic profiles and target engagement.

Key Points: 
  • Seelos is currently delivering SLS-007 via an adeno-associated virus (AAV) in a preclinical study designed to establish the in vivo pharmacokinetic and pharmacodynamic profiles and target engagement.
  • SLS-007 is a family of rationally designed peptide inhibitors that target the non-amyloid component core (NACore) of -synuclein to inhibit protein aggregation in patients with PD.
  • Recent in vitro and cell culture research have shown that SLS-007 has the potential to stop the propagation and seeding of -synuclein aggregates.
  • For more information, please visit our website: http://seelostherapeutics.com , the content of which is not incorporated herein by reference.